GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BSP:BIIB34) » Definitions » Additional Paid-In Capital

Biogen (BSP:BIIB34) Additional Paid-In Capital : R$2,705 Mil(As of Sep. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Biogen Additional Paid-In Capital?


Biogen's quarterly additional paid-in capital increased from Mar. 2024 (R$1,641 Mil) to Jun. 2024 (R$2,195 Mil) and increased from Jun. 2024 (R$2,195 Mil) to Sep. 2024 (R$2,705 Mil).

Biogen's annual additional paid-in capital declined from Dec. 2021 (R$386 Mil) to Dec. 2022 (R$384 Mil) but then increased from Dec. 2022 (R$384 Mil) to Dec. 2023 (R$1,482 Mil).


Biogen Additional Paid-In Capital Historical Data

The historical data trend for Biogen's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Additional Paid-In Capital Chart

Biogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 385.66 384.49 1,482.19

Biogen Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,196.15 1,482.19 1,640.84 2,194.84 2,705.22

Biogen Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Biogen Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Biogen's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen Business Description

Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Biogen Headlines

No Headlines